A randomized phase II trial of carboplatin with or without nivolumab in first-line metastatic triple-negative breast cancer (DFCI/HCC 17-512)
This research study is studying a drug called Carboplatin with or without another study drug, Nivolumab as a possible treatment for triple-negative breast cancer that has spread to other parts of the body.